On March 15, 2026, Eli Lilly announced that Orforglipron, its oral long-acting GLP-1 receptor agonist, was approved by the FDA for the treatment of obesity and overweight in adults.

It is the world’s first approved once-daily oral GLP-1, eliminating the pain of injections.

As patents for semaglutide expire, more than 10 Chinese companies have started generic drug applications, greatly boosting demand for peptide CDMO services.